Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Toni K. Choueiri"'
Autor:
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective i
Externí odkaz:
https://doaj.org/article/f27c30f1bd8e406580492b76ee1bb216
Autor:
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis,
Externí odkaz:
https://doaj.org/article/08953196fa7443bbb663ea7061737037
Autor:
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/fb97b853f0ab49559f8e621718cfb4a1
Autor:
Rajesh Kaldate, Eric Jonasch, Robert J. Motzer, Bernard Escudier, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, E. Wang, Toni K. Choueiri, Daniel J. George, Dana T. Aftab, Christian Scheffold, Nizar M. Tannir
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis, plasma b